Asset Details
Do you wish to reserve the book?
Covid-19 Boosters — Where from Here?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Covid-19 Boosters — Where from Here?
Do you wish to request the book?
Covid-19 Boosters — Where from Here?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Covid-19 Boosters — Where from Here?
2022
Overview
On December 10, 2020, Pfizer presented results from a 36,000-person, two-dose, prospective, placebo-controlled trial of its Covid-19 messenger RNA (mRNA) vaccine, BNT162b2, to the Food and Drug Administration (FDA).
1
The vaccine was 95% effective at preventing severe illness in all age groups, independent of coexisting conditions or racial or ethnic background. A remarkable result. Six months later, studies showed that protection against severe disease was holding up.
2
The results of these epidemiologic studies were consistent with those of immunologic studies showing long-lived, high frequencies of Covid-19–specific memory B and T cells, which mediate protection against severe disease.
3
In September 2021, . . .
Publisher
Massachusetts Medical Society
